Company intelligence / Profile preview

HoneyNaps

Ownership: Private
Development stage: Commercial

Overview

HoneyNaps has developed FDA-approved AI-powered software ("SOMNUM") for real-time analysis of multi-channel biosignals to diagnose sleep disorders. Its digital therapeutic "SOMNUM Medella" has been designated an innovative medical device by South Korea's MFDS. The company’s solutions are used in clinical settings in the US and South Korea. Clinical results show rapid (<5 min) automated diagnosis with high accuracy compared to manual expert review.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceDigital therapeuticSoftware as a Medical Device (SaMD)Artificial intelligence-based diagnostic software
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

SOMNUM

Commercial

Indications: Sleep disorders

Partnerships

Major university hospitals across the US through Boston-based branch officeIn talks with Big Pharma for copyright contracts and global commercialization of digital therapeutics

Beyond the preview

Go deeper on HoneyNaps.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HoneyNaps.

Explore the full profile